Niagen Bioscience Inc (NAGE) vs Entrada Therapeutics, Inc. (TRDA)

A side-by-side comparison of Niagen Bioscience Inc and Entrada Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Niagen Bioscience Inc logo
NAGE
Niagen Bioscience Inc
$214M
$2.69HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Entrada Therapeutics, Inc. logo
TRDA
Entrada Therapeutics, Inc.
$210M
$5.42HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — NAGE vs TRDA

growth of $100 · dividends reinvested · last 5y
NAGE -56.4% (-15.3%/yr)TRDA -77.1% (-25.5%/yr)NAGE compounded faster over this window
50100150200Start $10020222023202420252026$44$23
NAGE TRDA

NAGE vs TRDA: by the numbers

  • •NAGE is the larger company ($214M vs $210M market cap).
  • •NAGE is profitable (12.39% net margin) while TRDA runs a net loss (-3537.73%).

Metrics side by side

Valuation

MetricNAGETRDA
P/E ratio14.43N/A
Forward P/E18.65N/A
P/S ratio1.6644.90
P/B ratio2.600.90
EV / EBITDA14.36N/A
FCF yield2.65%N/A

Profitability

MetricNAGETRDA
Gross margin64.24%83.89%
Operating margin6.67%-613.66%
Net margin12.39%-3537.73%
ROE19.38%-71.02%
ROIC8.84%-63.61%

Growth (annualized)

MetricNAGETRDA
Revenue CAGR (5Y)15.80%N/A
Total return CAGR (5Y)-15.72%N/A

Frequently asked

Is NAGE or TRDA more profitable?
NAGE runs the higher net margin — NAGE at 12.39% versus TRDA at -3537.73%.

Go deeper

Full NAGE analysisFull TRDA analysisInteractive comparison tool

Dig into the metrics

Niagen Bioscience P/E ratioNiagen Bioscience ROEEntrada Therapeutics ROENiagen Bioscience operating marginEntrada Therapeutics operating marginNiagen Bioscience revenue growthEntrada Therapeutics revenue growthNiagen Bioscience free cash flowEntrada Therapeutics free cash flow

Niagen Bioscience & Entrada Therapeutics appear in these rankings

Fastest Revenue Growth StocksLowest P/E Ratio Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.